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By merging computational systems modeling and experimental approaches, we have uncovered treatments
reprogramming pro-angiogenic monocytes present in breast tumor into immunologically potent cells capable of
mediating an anti-tumor immune response. The unraveled pathways and ligands which underlie monocyte
pro-angiogenic activity have a strong predictive value for breast cancer patient relapse – free survival.
Tumor-associated monocytes are
highly plastic cells which support both
tumor angiogenesis and metastasis but are
also able to promote specific anti-tumor
immune response.1-3 These contrasting
biological activities are mediated by
monocytes with distinct functional polari-
zation ultimately dictated by tumor
microenvironmental cues.2 TIE-2-express-
ing monocytes (TEM) critically account
for tumor vascularization and growth in
mouse models4 however, the molecular
basis of their pro-angiogenic activity
remains largely unknown. We observed
that once blood monocytes reach the
breast tumor microenvironment they dra-
matically increase their pro-angiogenic
activity and expression of TIE-2 and vas-
cular endothelial growth factor receptor-1
(VEGFR-1). Elucidating the regulatory
mechanisms controlling TEM fate and
behavior is crucial for defining therapeutic
intervention points aimed at driving TEM
toward immunologically potent cells.
However, bearing in mind the combinato-
rial nature of intervention points, the
extraordinary heterogeneity of the tumor
microenvironment and the scarcity of
tumor monocytes, this challenge could
not be tackled through traditional experi-
mentation alone. Thanks to a combined
use of computational modeling and
experimental approaches, we have recently
uncovered treatment combinations capa-
ble of reprogramming TEM in breast
tumors and further, shown that the corre-
sponding pathways impact relapse – free
survival of breast cancer patients.5
Boolean models are powerful in
describing qualitatively large scale systems’
dynamics and predicting effective inter-
ventions6 that have proven successful in
drug discovery, cancer diagnostic and
treatment7,8. A Boolean network consists
of a set of nodes whose state is binary in
nature (on or off) and is determined by
other nodes in the network through Bool-
ean regulatory functions (activation or
inhibition).6 Our model was drawn on to
predict the treatments controlling TEM
pro-angiogenic activity and based exclu-
sively on experimentally-derived data. We
selected twenty “nodes” which are mono-
cyte markers, angiogenic and inflamma-
tory receptors or ligands expressed by
TEM or components of the breast tumor
microenvironment. Our approach
entailed five main steps depicted in
Fig. 1A. Causal relationships between the
nodes were assessed by perturbation
experiments (typically one or two ligands)
and used to define the Boolean functions
of the dynamical network. A Boolean
steady state of the network corresponds to
a TEM state which evolves by transition-
ing to another state in response to a per-
turbation. Finally, the model stabilizes in
different steady-states (attractors) and
modeling of transitions induced by pertur-
bations is a way to identify the key molec-
ular mechanisms controlling cell
functions.6
Hence, we exposed TEM to twelve dis-
tinct perturbations consisting of angio-
genic factors (ligands of TIE-2 and
VEGFR-1) either alone or in combination
with TNF-a or TGF-b and changes in
TEM phenotype, angiogenic activity and
paracrine secretion profile were assessed
and used as foundations for the model
(Fig. 1A, experimentation block). These
experimental data sets were assembled,
integrated and relevant causality regula-
tion links between nodes filtered accord-
ing to their amplitude, reproducibility
and consistency. In this way, 74 out of
924 possible links were retained as Bool-
ean functions and integrated into an
algorithm for computing Minimal Inter-
vention Set (MIS) of the obtained dynam-
ical network9 (Fig. 1A, system modeling
block). MIS patterns represent a set of
simultaneous minimal perturbations to
force the network into a desired steady
state (attractor). We considered two
attractors corresponding to peripheral
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blood and tumor TEM characterized by
their low and high expression of TIE-2
and VEGFR-1, respectively, and mirror-
ing their pro-angiogenic activity. We
assigned TIE-2 and VEGFR-1 nodes a
fixed polarity in the model to predict the
minimal perturbations transitioning blood
TEM into tumor TEM and vice versa
(Fig. 1B). Only one perturbation was pre-
dicted to promote TEM pro-angiogenic
activity and was validated experimentally.
Out of 11 perturbations predicted to
dampen TEM pro-angiogenic activity, six
could be addressed experimentally and
five were validated using tumor TEM
(Fig. 1B). The vast majority of these per-
turbations consisted in triple treatments
and, by way of comparison, a traditional
experimentation would have required
1350 experiments (Fig. 1A).
Further and most importantly, func-
tional and gene expression analyses
revealed that, in response to anti-angio-
genic perturbations, breast tumor TEM
reverted from pro-angiogenic suppressive
cells into cells sharing features of myeloid-
derived dendritic cells which were able to
mediate an anti-tumoral immune T cell
response.5,10 Finally, we show that the
unraveled pathways and ligands underly-
ing TEM pro-angiogenic activity have a
strong predictive value for breast cancer
patient relapse – free survival (Fig. 1A).
Experimental validations indicated that
our model accurately captured TEM
behavior and was able to frame efficiently
the experimentation. Our primary chal-
lenge was the integration of multi-scale
experimental data sets and in particular
the need to consider the complexity and
hierarchical nature of processes that con-
trol both phenotype/function and differ-
entiation of monocytes in response to
perturbations. A second challenge arose
from the inherent natural heterogeneity of
patient monocytes and the need to model
relatively sparse data from distinct individ-
uals. Although Boolean models can easily
serve as a valuable tool in a broad spec-
trum of cellular questions, only few stud-
ies have reported experimental validations
of in silico predictions. To the best of our
knowledge, ours is the first study predict-
ing combination of treatments validated
experimentally using patient cells and
presents an opportunity for the rational
design of novel therapies combining
immune checkpoint inhibitors with drugs
targeting epigenetic modifications and
metabolism.
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